X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs PLETHICO PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA PLETHICO PHARMA TORRENT PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 36.6 -1.1 - View Chart
P/BV x 6.5 0.0 38,553.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
PLETHICO PHARMA
Mar-14
TORRENT PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,550395 392.5%   
Low Rs1,14431 3,653.4%   
Sales per share (Unadj.) Rs354.7604.4 58.7%  
Earnings per share (Unadj.) Rs40.132.5 123.4%  
Cash flow per share (Unadj.) Rs64.251.3 125.1%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.1473.6 57.7%  
Shares outstanding (eoy) m169.2234.08 496.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.80.4 1,076.9%   
Avg P/E ratio x33.66.6 512.2%  
P/CF ratio (eoy) x21.04.2 505.1%  
Price / Book Value ratio x4.90.5 1,095.7%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8977,262 3,138.0%   
No. of employees `00014.7NA-   
Total wages/salary Rs m11,3531,596 711.3%   
Avg. sales/employee Rs Th4,083.0NM-  
Avg. wages/employee Rs Th772.3NM-  
Avg. net profit/employee Rs Th461.3NM-  
INCOME DATA
Net Sales Rs m60,02120,598 291.4%  
Other income Rs m2,988386 773.5%   
Total revenues Rs m63,00920,984 300.3%   
Gross profit Rs m13,4932,818 478.9%  
Depreciation Rs m4,086642 636.2%   
Interest Rs m3,0851,593 193.6%   
Profit before tax Rs m9,310969 961.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529-138 -1,827.4%   
Profit after tax Rs m6,7811,107 612.7%  
Gross profit margin %22.513.7 164.3%  
Effective tax rate %27.2-14.3 -190.1%   
Net profit margin %11.35.4 210.3%  
BALANCE SHEET DATA
Current assets Rs m52,62318,877 278.8%   
Current liabilities Rs m52,02211,896 437.3%   
Net working cap to sales %1.033.9 3.0%  
Current ratio x1.01.6 63.7%  
Inventory Days Days12036 332.8%  
Debtors Days Days76198 38.5%  
Net fixed assets Rs m85,0169,861 862.2%   
Share capital Rs m846341 248.4%   
"Free" reserves Rs m45,37612,331 368.0%   
Net worth Rs m46,22216,139 286.4%   
Long term debt Rs m41,1154,706 873.7%   
Total assets Rs m142,43233,146 429.7%  
Interest coverage x4.01.6 249.9%   
Debt to equity ratio x0.90.3 305.1%  
Sales to assets ratio x0.40.6 67.8%   
Return on assets %6.98.1 85.0%  
Return on equity %14.76.9 213.9%  
Return on capital %14.212.3 115.5%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m14,5804,402 331.2%   
Fx outflow Rs m3,6003,184 113.1%   
Net fx Rs m10,9801,219 901.1%   
CASH FLOW
From Operations Rs m8,9422,437 366.9%  
From Investments Rs m-47,070-6,265 751.3%  
From Financial Activity Rs m34,1742,490 1,372.4%  
Net Cashflow Rs m-3,655-1,337 273.3%  

Share Holding

Indian Promoters % 71.5 82.7 86.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 4.3 163.3%  
FIIs % 12.6 5.5 229.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 7.5 117.3%  
Shareholders   26,511 10,665 248.6%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 22, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - SHASUN PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS